# Arbor Biotechnologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/arbor-biotechnologies

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.arbor.bio/
- Total disclosed funding: $289M
- Latest round: Series C (Mar 18, 2025)
- Investors on record: 24

## About

Founded in 2016, based in Massachusetts, US, Arbor Biotechnologies, Inc. is a biotechnology company developing genetic medicines. The company was co-founded by Feng Zhang, Winston Yan, David Scott, and David Walt. In October 2025, Arbor Biotechnologies, Inc. raised an undisclosed amount in venture funding from new investors Samsung Ventures.

The company is focused on identifying and developing a new generation of genetic therapies using fully owned genomic editors discovered using its machine learning and AI discovery platform. Arbor identifies, screens, and constructs novel editing enzymes and effectors using the discovery platform, which can subsequently be customized to the underlying cause of disease to provide curative medicine for patients. 

Revenue is primarily derived from strategic partnerships, licensing agreements for its gene editing technologies, and collaborations with pharmaceutical companies.

The company will use the funding to accelerate the development of transformative gene editing therapies for severe genetic diseases of the liver and CNS.

## Funding rounds

- Series C, Mar 18, 2025, $74M — ARCH Venture Partners, T Rowe Price, Temasek Holdings, Surveyor Capital, ArrowMark Partners, Piper Sandler, Vertex Pharmaceuticals Incorporated, Partners Investment, Ally Bridge Group, Revelation Partners, TCG Crossover Management, Deep Track Capital, QIA, Kerna Ventures
- Series B, Oct 29, 2021, $215M — ARCH Venture Partners, T Rowe Price, Temasek Holdings, Tekla Capital Management, Surveyor Capital, ArrowMark Partners, Piper Sandler, GreatPoint Ventures, Vertex Pharmaceuticals Incorporated, Ally Bridge Group, Janus Henderson Investors, Tao Capital Partners, Illumina Ventures, Section 32, Ridgeback Asset Management, Woodline Partners, Logos Capital, TCG Crossover Management, Deep Track Capital, Ono Venture Investment

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series B, Series C
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series B, Series C
- Temasek Holdings — Series B, Series C
- Tekla Capital Management (https://capitalatlas.ai/funds/tekla-capital-management) — Series B
- Surveyor Capital — Series B, Series C
- ArrowMark Partners — Series B, Series C
- Piper Sandler (https://capitalatlas.ai/funds/piper-sandler) — Series B, Series C
- GreatPoint Ventures (https://capitalatlas.ai/funds/greatpoint-ventures) — Series B
- Vertex Pharmaceuticals Incorporated — Series B, Series C
- Ally Bridge Group (https://capitalatlas.ai/funds/ally-bridge-group) — Series B, Series C
- Janus Henderson Investors — Series B
- Tao Capital Partners (https://capitalatlas.ai/funds/tao-capital-partners) — Series B
- Illumina Ventures (https://capitalatlas.ai/funds/illumina-ventures) — Series B
- Section 32 (https://capitalatlas.ai/funds/section-32) — Series B
- Ridgeback Asset Management — Series B
- Woodline Partners — Series B
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series B
- TCG Crossover Management (https://capitalatlas.ai/funds/tcg-crossover-management) — Series B, Series C
- Deep Track Capital (https://capitalatlas.ai/funds/deep-track-capital) — Series B, Series C
- Ono Venture Investment (https://capitalatlas.ai/funds/ono-venture-investment) — Series B
- Partners Investment (https://capitalatlas.ai/funds/partners-investment) — Series C
- Revelation Partners (https://capitalatlas.ai/funds/revelation-partners) — Series C
- QIA — Series C
- Kerna Ventures — Series C